Objective: To evaluate the safety and efficacy of combining deferiprone(DFP)and deferoxamine(DFO)in iron chelation therapy in patients with thalassemia.
To prevent complications from an existing blood or bleeding disorder, such as sickle cell disease, thalassemia, or anaemia caused by kidney disease, haemophilia, or von Willebrand disease.